Cord blood banking is defined as the collection and storage of stem cells present within the umbilical cord blood of a newborn for future medical use. Umbilical cord blood is rich in a type of stem cell known as a hematopoietic stem cell (HSC). A large market for the storage of these cells has come into existence over the past 30 years, with public and private cord blood banks now present in all major healthcare markets worldwide. [Read more…]
RANCHO CORDOVA, Calif., Nov. 19, 2018— Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that its device subsidiary, ThermoGenesis® Corp., has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its proprietary AXP® II AutoXpress® Platform (AXP II) for clinical blood banking.
The AXP II, in combination with the Company’s companion, single-use, cell separation set provides automated, rapid and reliable harvest of stem and progenitor cells from collected units of umbilical cord blood in a “functionally-closed” sterile system. [Read more…]
Umbilical cord blood present at birth contains a type of non-controversial stem cell. Called hematopoietic stem cells or HSCs, these stem cells can be used to treat up to 80 different conditions, including a range of childhood blood diseases and cancers. There are stem cells present within the umbilical cord tissue called mesenchymal stem cells (MSCs). Stem and progenitor cells are also present in a range of other birth tissues, including placental blood and tissue and amniotic fluid and tissue.
The collection and storage of stem cells from cord blood is called cord blood banking and the companies that store these cells are called cord blood banks. In this way, many cellular “gifts” can be collected during a live birth. These valuable cells can then be stored for future therapeutic use by the child, the family, or the public at large.
If the medical discovery of stem cells from cord blood interests you, read on to learn about its latest developments. [Read more…]
Boston Biolife announces upcoming Regenerative Medicine Workshop to be held in Orlando, FL, from November 29 – December 2, 2018.
Boston BioLife is excited to announce its upcoming Regenerative Medicine Workshop in Orlando, Florida at the Omni Resort at Championsgate, November 29 – December 2nd, 2018. This is an amazing resort destination with two champion 18-hole golf courses that is family-friendly, offers spa amenities, and includes close proximity to all of the Disney Parks. [Read more…]
HemaCare Corporation (OTCMKTS: HEMA) is a long-standing leader in the customization and supply of human-derived biological products and services for biomedical research and cell therapy. Within the U.S. and internationally, the company is well-known for its network of FDA-registered, GMP/GTP-compliant collection centers where it collects human biological materials. Types of cellular materials collected and supplied by Hemacare include peripheral blood, bone marrow, and cord blood, each of which it isolates into primary cells types and can supply to customers in both fresh and frozen states. [Read more…]